Core Viewpoint - Yiming Oncology-B (01541) experienced a significant stock increase of over 9%, currently trading at 7.31 HKD, following the approval of its clinical research protocol for IMM0306 by the National Medical Products Administration [1] Group 1: Company Developments - Yiming Oncology announced that it has received approval for the Phase III clinical study of IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma [1] - IMM0306 is the world's first dual-targeting bispecific molecule targeting CD47 and CD20, designed to block the "don't eat me" signal, thereby activating macrophages and NK cells [1] - The drug preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, which could enhance treatment outcomes [1] Group 2: Market Reaction - Following the announcement, Yiming Oncology's stock price rose by 7.98%, with a trading volume of 10.70 million HKD [1]
港股异动 | 宜明昂科-B(01541)午后涨超9% IMM0306的III期临床研究方案获CDE许可